The study of HMOX1 DNA methylation and gene expression and the diagnostic potential of miR-153-3p in preeclampsia.

IF 3 4区医学 Q2 GENETICS & HEREDITY Epigenomics Pub Date : 2024-03-01 Epub Date: 2024-02-27 DOI:10.2217/epi-2023-0377

Somayeh Rahimi, Nayebali Rezvani, Saeed Khazayel, Nazanin Jalilian, Ebrahim Shakiba, Fatemeh Khadir, Kheirollah Yari, Zohreh Rahimi

{"title":"The study of HMOX1 DNA methylation and gene expression and the diagnostic potential of miR-153-3p in preeclampsia.","authors":"Somayeh Rahimi, Nayebali Rezvani, Saeed Khazayel, Nazanin Jalilian, Ebrahim Shakiba, Fatemeh Khadir, Kheirollah Yari, Zohreh Rahimi","doi":"10.2217/epi-2023-0377","DOIUrl":null,"url":null,"abstract":"Background: The objective was to elucidate the potential epigenetic regulatory mechanism in HMOX1 expression in preeclampsia. Materials & methods: HMOX1 promoter DNA methylation was evaluated in the placental tissue and blood of preeclamptic and normotensive pregnant women. HMOX1 and miR-153-3p gene expression were assessed in placental tissue and peripheral blood mononuclear cells (PBMCs). Related microarray datasets in the Gene Expression Omnibus database were also analyzed. Results: In placental tissue, despite HMOX1 expression downregulation, there was no significant change in HMOX1 methylation. In PBMCs, there was no significant alteration in HMOX1 expression, while hypomethylation was observed in blood. The miR-153-3p expression increased in the placental tissue and in the PBMCs of preeclampsia. Conclusion: DNA methylation does not affect HMOX1 expression, while miR-153-3p might be a biomarker for preeclampsia.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"389-401"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/epi-2023-0377","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The objective was to elucidate the potential epigenetic regulatory mechanism in HMOX1 expression in preeclampsia. Materials & methods: HMOX1 promoter DNA methylation was evaluated in the placental tissue and blood of preeclamptic and normotensive pregnant women. HMOX1 and miR-153-3p gene expression were assessed in placental tissue and peripheral blood mononuclear cells (PBMCs). Related microarray datasets in the Gene Expression Omnibus database were also analyzed. Results: In placental tissue, despite HMOX1 expression downregulation, there was no significant change in HMOX1 methylation. In PBMCs, there was no significant alteration in HMOX1 expression, while hypomethylation was observed in blood. The miR-153-3p expression increased in the placental tissue and in the PBMCs of preeclampsia. Conclusion: DNA methylation does not affect HMOX1 expression, while miR-153-3p might be a biomarker for preeclampsia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

子痫前期 HMOX1 DNA 甲基化和基因表达的研究以及 miR-153-3p 的诊断潜力。

研究背景目的：阐明子痫前期 HMOX1 表达的潜在表观遗传调控机制。材料与方法：评估子痫前期和血压正常孕妇胎盘组织和血液中 HMOX1 启动子 DNA 甲基化的情况。评估胎盘组织和外周血单核细胞（PBMCs）中 HMOX1 和 miR-153-3p 的基因表达。同时还分析了基因表达总库（Gene Expression Omnibus）数据库中的相关芯片数据集。结果在胎盘组织中，尽管 HMOX1 表达下调，但 HMOX1 甲基化没有显著变化。在 PBMCs 中，HMOX1 的表达没有明显变化，而在血液中观察到了低甲基化。在子痫前期的胎盘组织和 PBMCs 中，miR-153-3p 表达增加。结论DNA甲基化不会影响HMOX1的表达，而miR-153-3p可能是子痫前期的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.